دورية أكاديمية
Long term follow up in 183 high grade meningioma: A single institutional experience
| العنوان: | Long term follow up in 183 high grade meningioma: A single institutional experience |
|---|---|
| المؤلفون: | Simonetti G., Silvani A., Tramacere I., Farinotti M., Legnani F., Pinzi V., Pollo B., Erbetta A., Gaviani P. |
| المساهمون: | Simonetti, G, Silvani, A, Tramacere, I, Farinotti, M, Legnani, F, Pinzi, V, Pollo, B, Erbetta, A, Gaviani, P |
| بيانات النشر: | Elsevier B.V. NL |
| سنة النشر: | 2021 |
| المجموعة: | Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| مصطلحات موضوعية: | Anaplastic meningioma, Atypical meningioma, Chemotherapy, High grade meningioma, Radiotherapy |
| الوصف: | Introduction: Meningiomas are usually considered benign lesions, however a proportion of them shows a more aggressive behavior, defined high-grade meningiomas (HGM). Effective medical treatments are lacking, especially at the time of recurrence. Methods: Through a retrospective analysis, we examined epidemiological, diagnostic, therapeutic, recurrence information and survival data of HGM treated at our institution between 2010 and 2018. Results: 183 patients (105 females and 78 males), with median age of 58 years (25–88), were included; 168 were atypical, 12 anaplastic, 3 rhabdoid. Overall, m-PFS was 4.2 years, and m-OS was 10.3 years. Gross-total resection had a 5-year survival rate of 95% compared with subtotal/partial resection (86% and 67%) (p = 0.002). Higher expression of Ki-67/MIB-1 seems associated with higher risk of death (HR:1.06 with 95% CI, 1.00–1.12, p = 0.03). No statistically significant differences were seen in survival between the group managed with a wait-and-see strategy vs the group treated with RT while a difference on PFS was seen (4.1 years vs 5.2 years p = 0.03). After second recurrence, the most employed treatments were systemic therapies with a very limited effect on disease control. Conclusions: Data confirmed the aggressive behavior of HGM. The extent of resection seems to correlate with a favorable outcome regardless histological subtypes. The role of RT remains controversial, with no statistically significant impact on OS but a possible role on PFS. Recurrent HGM remains the real challenge, to date no chemotherapies are able to achieve disease control. Future research should focus on biological/molecular predictors in order to achieve a patient-tailored treatment. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34293659; info:eu-repo/semantics/altIdentifier/wos/WOS:000713696800009; volume:207; journal:CLINICAL NEUROLOGY AND NEUROSURGERY; http://hdl.handle.net/10281/325091Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85110531803 |
| DOI: | 10.1016/j.clineuro.2021.106808 |
| الإتاحة: | https://doi.org/10.1016/j.clineuro.2021.106808Test http://hdl.handle.net/10281/325091Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.2595C8DC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.clineuro.2021.106808 |
|---|